# A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients

> **NCT00551850** · PHASE1 · COMPLETED · sponsor: **AVEO Pharmaceuticals, Inc.** · enrollment: 37 (actual)

## Conditions studied

- Advanced Cancer
- Refractory Cancer

## Interventions

- **DRUG:** AV-412

## Key facts

- **NCT ID:** NCT00551850
- **Lead sponsor:** AVEO Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2009-10
- **Final completion:** 2010-05
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2011-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00551850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00551850, "A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00551850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*